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modah@pharm.kAbstract Fibrodysplasia ossiﬁcans progressiva (FOP) is a rare autosomal dominant congenital
disorder characterized by progressive heterotopic ossiﬁcation in muscle tissues. A constitutively
activated mutation of a bone morphogenetic protein (BMP) receptor, ALK2, has been identiﬁed
in patients with FOP. We report here that four structurally related compounds, lucilactaene,
hydroxylucilactaene, NG-391 and NG-393, produced by fungal strain Fusarium sp. B88, inhibit
BMP signaling in vitro. Alkaline phosphatase activity, a marker enzyme of osteoblastic
differentiation, was decreased in C2C12 myoblasts stably expressing mutant ALK2 by treatment
with those compounds with IC50 values of 5.7, 6.8, 6.9 and 6.1 mM, respectively. Furthermore,
NG-391 and NG-393 inhibited BMP-speciﬁc luciferase reporter activity, which is directly regulated
by transcription factor Smads, with IC50 values of 1.4 and 2.1 mM, respectively. These ﬁndings
suggest that these fungal metabolites may provide a new direction in the development of FOP
therapeutics.
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Bone is a connective tissue that guarantees the protection
and support of organ function. Contrary to the common view,
bone is a dynamic tissue that constantly undergoes turnover in
order to maintain stability and remodeling. Bone remodeling
is a process coupled with bone resorption and bone formation
that determines bone structure and quality during adult life.
Osteoblasts, bone-forming cells, are derived from the embryo-
nic mesoderm. During the early stages of osteoblast differ-
entiation, several molecules such as bone morphogenetic
proteins (BMPs), transforming growth factor-bs (TGF-bs),
leukemia inhibitor factor (LIF), ﬁbroblast growth factors
(FGFs) and platelet-derived growth factors (PDGFs), drive
the differentiation of stem cells to inducible osteoprogenitors
(stromal mesenchymal stem cells) and then to determined
osteoprogenitors1. Among these molecules, BMPs are reported
as unique factors, which can induce ectopic bone formation
in muscle2.
The BMP signaling pathway is one of the most highly
conserved signaling pathways among the bone remodeling
systems3,4. The BMP signal starts with binding to heterote-
trameric transmembrane complexes of type I and type II
BMP receptors. Four type I receptors, ALK1, ALK2, ALK3/
BMPR-IA and ALK6/BMPR-IB, and three type II receptors,
BMPR-II, ActR-II and ActR-IIB, have been reported5.
Following ligand binding, serines and threonines in the
glycine/serine (GS) domain of type I receptor are phosphory-
lated by the constitutively activated type II receptor. Thus, the
BMP type I receptor is activated by the phosphorylation
event, which transmits downstream to BMP pathway-speciﬁc
Smad1/5/8 and p38 MAPK6. Furthermore, phosphorylated
Smad1/5/8 forms complexes with Smad4, and they move to
the nucleus and work as transcription factors to express early
responsive genes such as Id1 (an inhibitory protein for
myogenesis). Smads bind to a GC-rich BMP responsive
element (BRE) in the early responsive genes6. The cells
activated via BMP signaling differentiate to osteoblastic cells,
which express typical differentiation markers such as alkaline
phosphatase (ALP), osteocalcin and osteopontin.
Fibrodysplasia ossiﬁcans progressiva (FOP) is a congenital
disorder of progressive and widespread postnatal ossiﬁcation
of soft tissues7. Ectopic bone formation in FOP occurs
through an endochondral pathway in which cartilage is
formed initially at the site and is subsequently replaced by
bone8,9. FOP results in severe debilitation and reduces the life
span due to joint fusion and restrictive lung disease with
thoracic involvement. The median age of survival is approxi-
mately 41 years10. Surgical attempts to operatively remove
heterotopic bone have commonly led to episodes of explosive
and painful new bone growth called ‘‘ﬂare-ups’’11. Shore et al.12
found a recurrent heterozygous mutation, c.617G-A, in the
ACVR1/ALK2 gene in both familial and sporadic patients
with FOP that causes an amino acid substitution of Arg to His
at codon 206 (R206H) of ALK2. Since this mutation has been
shown to constitutively activate ALK2, speciﬁc inhibitors of
ALK2 could offer therapeutic beneﬁt for FOP. Consequently,
the quest for novel pharmacological agents that target speciﬁc
steps of FOP has signiﬁcantly intensiﬁed. As a result, synthetic
dorsomorphin13,14, originally discovered as an AMP kinase
inhibitor, was found to selectively inhibit BMP signal-
ing induced by type I receptors such as ALK2, ALK3 andALK613. Cuny et al.15 improved dorsomorphin to successfully
obtain more potent derivative LDN-193189, which prevented
ectopic bone formation in mice carrying an active mutant
ALK2 and attenuated lesions in the remainder16. C2C12
myoblasts, derived from murine thigh muscle, inhibit myogen-
esis and express osteoblastic phenotypes by treatment with
BMPs or over-expression of constitutively activated BMP type
I receptors6. C2C12 cells have been widely used for studies
of osteoblast differentiation induced by BMP signaling
in vitro17–19.
In this study, we screened for potent inhibitors of osteo-
blastic differentiation induced by BMP signaling using a stable
ALK2(R206H)-expressing C2C12 cell line (abbreviated as
C2C12(R206H) cells), which exhibited ALP activity more
quickly and more strongly than original C2C12 cell line, to
develop FOP chemotherapy20. After testing the natural pro-
duct library (217 compounds) and the actinomycetal and
fungal culture broths (9831 samples) in this screening, we
found four structurally related fungal metabolites, lucilac-
taene21, hydroxylucilactaene22, NG compounds (NG-391 and
NG-393)23,24, from the culture broth of Fusarium sp. B88.
Moreover, NG-391 and NG-393 inhibited a BMP-speciﬁc
luciferase reporter activity, which is directly regulated by tran-
scription factor Smads. These ﬁndings suggest that these fungal
metabolites may provide a new direction in the development of
FOP therapeutics.2. Materials and methods
2.1. Materials
Fusarium sp. B88 was isolated from the body of a grasshopper
collected in 2006 on Ishigakijima where is a small southern
island belonging to Okinawa in Japan. This fungus was
incubated in BYK-1 broth (25 g RISO VIALONE NANO
RICE (Japan Europe Trading Co., Ltd., Tokyo, Japan) and
0.6 g DifcoTM Potato Dextrose Broth (Becton, Dickinson
Company, France) in 25 mL H2O) at 27 1C for 14 day under
static conditions. The culture broth (1 kg) was extracted with
acetone. After the acetone extracts was concentrated, the
resulting aqueous solution was extracted with EtOAc. The
EtOAc layer was dried over anhydrous Na2SO4 and concen-
trated in vacuo to yield 2.3 g of solid material. The material
was dissolved in a small volume of CHCl3, applied to a silica
gel column (30 g, 70–230 mesh, Merck), and eluted stepwise
with 100:0, 100:1, 50:1, 10:1, 1:1 and 0:100 (v/v) of CHCl3–
CH3OH solvents (300 mL each). The CHCl3:CH3OH¼10:1
fraction was concentrated in vacuo to dryness to give a brown
material (66.0 mg). The material was ﬁnally puriﬁed by
preparative HPLC (column, PEGASIL ODS, 20 mm 250 mm,
Senshu Scientiﬁc Co.; solvent, 45% CH3CN; detection, UV
at 210 nm; ﬂow rate, 8.0 mL/min). Under these conditions,
hydroxylucilactaene, NG-391, NG393 and lucilactaene were
eluted as peaks with retention time of 21, 23, 28 and 38 min.
The pooled fractions were concentrated in vacuo to dryness
to give pure hydroxylucilactaene (1.9 mg), NG-391 (4.0 mg),
NG393 (2.3 mg) and lucilactaene (1.8 mg), respectively. The
MS and 1H NMR spectra of these compounds were identical
to those reported previously21–24. All these samples (1 mg
each) were dissolved in 1 mL CH3OH and used as assay
samples.
Alkaline phosphatase activity in BMP 253-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H tetrazolium
bromide (MTT) and p-nitrophenyl phosphate were purchased
from Sigma (St. Louis, MO, USA), Dulbecco’s modiﬁed
Eagle’s medium (DMEM), fetal bovine serum (FBS), penicil-
lin/streptomycin, diethnolamine and rhBMP-4 were purchased
from Nacalai Tesque (Kyoto, Japan), HyClone (Waltham,
MA, USA), Invitrogen (Carlsbad, CA, USA), Wako Pure
Chemical Industries (Osaka, Japan) and R&D Systems
(Mountain View, CA, USA), respectively.
2.2. Cell culture
C2C12 and C2C12 (R206H) cells20 were cultured in DMEM
supplemented with 15% FBS and 100 units/mL penicillin and
100 mg/mL streptomycin (hereafter referred to as medium A)
at 37 1C in 5.0% CO2. Both cells were subcultured once
every 3 day.
2.3. Assay for alkaline phosphatase in BMP-treated
C2C12 cells
Alkaline phosphatase (ALP) activity, a typical marker of
osteoblastic differentiation, was measured as described pre-
viously19. In brief, C2C12 (R206H) cells (7.5 103 cells/well)
in a 96-well plastic plate were cultured at 37 1C in 5.0% CO2.
Following overnight recovery, the culture media were replaced
with 100 mL fresh medium A containing rhBMP-4 (10 ng/mL)
and a sample (1 mL in CH3OH solution). After 48 h incuba-
tion, the cells were incubated for 60 min with 100 mL
substrate solution (100 mM diethanolamine, 0.5 mM MgCl2
and 1.0 mg/mL p-nitrophenylphosphate) at room temperature.
The reaction was terminated by adding 50 mL 3 M NaOH,
and the absorbance at 405 nm was measured with a
Power Wave 340 (BIO-TEK Instruments, Highland Park,
IL, USA).
2.4. Cytotoxicity
Cytotoxicity of a compound to C2C12 (R206H) cells was
evaluated by the MTT assay25. In brief, C2C12 (R206H) cells
(7.5 103 cells/well) were cultured in 96-well plates in theFigure 1 Structures of lucilactaene, hydroabsence or presence of a compound for 48 h at 37 1C in 5.0%
CO2. After incubation, the cells received 10 mL MTT solution
(5.5 mg/mL in phosphate-buffered saline), and were then
incubated at 37 1C for 3 h. A 90 mL aliquot of the lysis
solution (40% N,N-dimethylformamide, 2.0% CH3COOH,
20% SDS and 0.03 M HCl) was added to each well, and the
plates were incubated for 2 h. The absorbance at 550 nm of each
well was read with a Power Wave 340. Inhibition of cell growth
is deﬁned as (absorbance-sample/absorbance-control) 100%.
The IC50 value is deﬁned as a sample concentration that causes
50% inhibition of cell growth.
2.5. Reporter gene assay for monitoring BMP signaling
The effect of a compound on BMP signaling via Smads was
examined using a BMP-speciﬁc luciferase reporter, Id1WT4F-
luc, which is driven by four tandem copies of BRE in the Id1
gene6. In brief, C2C12 cells were inoculated at 1.0 104 cells/
well in 96-well plates with medium A and incubated for 24 h.
The cells were transfected with 200 ng of plasmid DNA (40 ng
of Id1WT4F-luc, 10 ng of phRL-SV40 and 150 ng of ALK2
(R206H)) using 0.5 mL of Lipofectamine 2000 (Invitrogen) in
OPTI-MEM (GIBCO) according to the manufacture’s proto-
col. After 2.5 h incubation, the culture medium was replaced
with 100 mL fresh DMEM containing 2.5% FBS without
penicillin and streptomycin. After additional 3 h incubation,
a compound (1 mL CH3OH solution) was added to each well
and cultured for 24 h. Both ﬁreﬂy and renilla luciferase
activities in the cells were determined using Dual Glo Luciferase
assay system (Promega, Madison, WI, USA).3. Results and discussion
In the present study, we screened microbial culture broths for
inhibitors of ALP activity of C2C12 (R206H) cells. As a result,
structurally related four compounds, lucilactaene21, hydroxylu-
cilactaene22, NG-39123 and NG-39323,24 (Fig. 1) were isolated
from a fungal strain Fusarium sp. B88. In fact, all of the
compounds inhibited ALP activity in a dose-dependent manner
with analogous IC50 values of 5.7, 6.8, 6.9 and 6.1 mM (Fig. 2).
Although they were originally reported as a cell cycle inhibitor21,xylucilactaene, NG-391 and NG-393.
Figure 2 Effect of lucilactaene, hydroxylucilactaene, NG-391 and NG-393 on ALP activity and cytotoxicity of C2C12 (R206H) cells.
C2C12 (R206H) cells (7.5 103cells/well) were cultured to 70% conﬂuence and then treated with lucilactaene (A), hydroxylucilactaene
(B), NG-391 (C) and NG-393 (D) in the presence BMP (10 ng/mL). After 48 h incubation, ALP activity (’) and cytotoxicity (K) were
measured as described in Section 2. Values are the mean7SD of three independent experiments.
Figure 3 Effect of lucilactaene, hydroxylucilactaene, NG-391
and NG-393 on BMP signaling in C2C12 (Id1-BRE) cells.
C2C12 cells (1.0 104 cells/well) were cultured for 24 h and then
Id1-WT4F-luc, phRL-SV40 and ALK2 (R206H) were co-trans-
fected to construct C2C12 (Id1-BRE) cells. After 2.5 h incubation,
the culture media were replaced with DEME containing 2.5%
FBS without penicillin and streptomycin. After another 3 h
incubation, the cells were treated with lucilactaene (K), hydro-
xylucilactaene (m), NG-391 (’) and NG-393 (~). Luciferase
activities in the cell extracts were determined using the Dual Glo
Luciferase assay system as described in Section 2. Values are the
mean7SD of three independent experiments.
Takashi Fukuda et al.26an anticancer analog22, promoters of nerve growth factor
production23 and mutagenic agents against the Salumonella24,
we ﬁrst showed that these compounds also inhibit ALP activity,
a key marker of osteoblast differentiation of C2C12 (R206H)
cells. No marked or very weak cytotoxic effects on C2C12
(R206H) cells were observed at the highest dose (30 mM) of each
compound in a MTT assay (Fig. 2).
The ALP activity is one of the markers of osteoblast
differentiation in vitro and in vivo. The induction of ALP
activity in C2C12 cells is an output through the multiple
intracellular events initiated by the activation of BMP recep-
tors. To examine direct effect of those compounds on BMP
signaling, we determined Id1WT4F-luc activity in C2C12 cells.
The luciferase activity in Id1WT4F-luc is driven by BRE in the
Id1 gene, which is recognized by a complex of phosphorylated
Smad1/5/8 and Smad4. Since Smad1/5/8 is phosphorylated by
BMP type I receptors including ALK2, the formation of Smad
complexes on BRE and the induction of reporter activity is
highly speciﬁc for BMP signal transduction. As shown in
Fig. 3, NG-391 and NG-393 inhibited luciferase activity of
Id1WT4F-luc in C2C12 cells with IC50 values of 1.4 and
2.1 mM, respectively. These concentrations were much lower
than those of cytotoxic effects. Lucilactaene and hydroxyluci-
lactaene showed no effect on luciferase activity at 2.5 mM
(Fig. 3), and inhibited the activity at 20 mM probably due to
cytotoxic effects.
Our ﬁndings suggest that NG-391 and NG-393 may inhibit
an early event(s) in BMP signal transduction because they
inhibited the BMP-speciﬁc luciferase reporter activity, which
expression is directly regulated by Smads. On the other hand,
lucilactaene and hydroxylucilactaene may inhibit a different
event(s) from that NG compounds. To the best of our
knowledge, this is the ﬁrst report of BMP signal inhibitors
of natural origin. BMP activity is controlled at multiple steps
in signal transduction. It was reported that BMP antagonists
such as noggin and follistatin inhibit a binding step of BMPs
to the receptors in the extracellular space26,27 and that an
intracellular domain-truncated type I receptor, BAMBI, inhi-
bits BMP signaling by acting as a dominant negative receptor
on the cell membrane28. In contrast, several types of BMP
inhibitors act in the intracellular spaces; FKBP-12 and
I-Smads, such as Smad6 and Smad7, bind to the GS domain
and kinase domain of the type I receptors, respectively, and
block the kinase activity29. The chemical BMP inhibitors,
dorsomorphin13,14 and LDN-19318915, have been shown to
bind to the ATP-binding pocket of the type I receptors toprevent phosphorylation of Smads30. Two types of protein
phosphatases, protein phosphatase Mg2þ-dependent 1A and
small C-terminal protein phosphatases, inhibits Smads and
further downstream effectors in BMP signaling31. Since NG-
391 and NG-393 inhibited BMP-induced ALP activity and the
luciferase reporter activity, these compounds may target a
step(s) between BMP binding to the receptor and activation of
Smads on the BRE. Further studies will be needed to elucidate
molecular mechanisms of the inhibition of BMP signaling by
the compounds found in this study. We expect that these
compounds will provide a new direction in the development of
FOP therapeutics.Acknowledgments
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